Immune globulin subcutaneous, human - klhw 20% solution (Xembify®, IGSC-C 20%) has a positive safety and tolerability profile in an open-label, multicenter, phase 3 study in primary immunodeficiency (PI)

被引：0

作者：

Wedner, H. James ^{[1
]}

Sleasman, John ^{[2
]}

Lumry, William ^{[3
]}

Hussain, Iftikhar ^{[4
]}

Harris, James ^{[5
]}

Mondou, Elsa ^{[6
]}

Lin, Jiang ^{[6
]}

Hames, Carrie ^{[6
]}

Querolt, Montse ^{[6
]}

Stein, Mark ^{[7
]}

机构：

[1] Washington Univ, St Louis, MO 63110 USA

[2] Duke Univ, Sch Med, Durham, NC 27706 USA

[3] AARA Res Ctr, Dallas, TX USA

[4] Vital Prospects Clin Res Inst PC, Tulsa, OK USA

[5] South Bend Clin Ctr Res, Allergy & Immunol, South Bend, IN USA

[6] Grifols, Barcelona, Spain

[7] Good Samaritan Hosp, Phoenix, AZ USA

来源：

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

095

引用

页码：AB31 / AB31

页数：1